Lipella Pharmaceuticals Inc.
LIPO
$0.31
$0.0311.80%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 389.80K | 470.20K | 519.90K | 536.40K | 483.50K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 389.80K | 470.20K | 519.90K | 536.40K | 483.50K |
| Cost of Revenue | 3.57M | 3.89M | 3.76M | 3.61M | 3.01M |
| Gross Profit | -3.18M | -3.42M | -3.24M | -3.08M | -2.52M |
| SG&A Expenses | 2.23M | 2.17M | 1.95M | 2.00M | 1.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.80M | 6.07M | 5.71M | 5.62M | 4.84M |
| Operating Income | -5.41M | -5.60M | -5.19M | -5.08M | -4.36M |
| Income Before Tax | -5.33M | -5.52M | -5.13M | -5.02M | -4.26M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.33 | -5.52 | -5.13 | -5.02 | -4.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.33M | -5.52M | -5.13M | -5.02M | -4.26M |
| EBIT | -5.41M | -5.60M | -5.19M | -5.08M | -4.36M |
| EBITDA | -5.41M | -5.59M | -5.19M | -5.08M | -4.36M |
| EPS Basic | -2.41 | -3.43 | -4.10 | -4.78 | -4.40 |
| Normalized Basic EPS | -1.51 | -2.14 | -2.57 | -2.99 | -2.75 |
| EPS Diluted | -2.42 | -3.43 | -4.11 | -4.78 | -4.41 |
| Normalized Diluted EPS | -1.51 | -2.14 | -2.57 | -2.99 | -2.75 |
| Average Basic Shares Outstanding | 12.12M | 8.69M | 5.34M | 4.19M | 3.83M |
| Average Diluted Shares Outstanding | 12.12M | 8.69M | 5.34M | 4.19M | 3.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |